Ventyx Biosciences Target of Unusually Large Options Trading (NASDAQ:VTYX)

Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) was the target of some unusual options trading on Tuesday. Investors bought 2,207 call options on the company. This is an increase of approximately 299% compared to the average daily volume of 553 call options.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of VTYX. Intech Investment Management LLC acquired a new stake in shares of Ventyx Biosciences in the third quarter worth $42,000. Charles Schwab Investment Management Inc. raised its position in Ventyx Biosciences by 3.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 485,101 shares of the company's stock valued at $1,058,000 after purchasing an additional 17,898 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in shares of Ventyx Biosciences by 19.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 568,479 shares of the company's stock worth $1,239,000 after purchasing an additional 92,753 shares in the last quarter. State Street Corp boosted its position in shares of Ventyx Biosciences by 0.8% in the third quarter. State Street Corp now owns 1,187,650 shares of the company's stock worth $2,589,000 after buying an additional 9,783 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Ventyx Biosciences in the third quarter valued at about $246,000. Hedge funds and other institutional investors own 97.88% of the company's stock.

Ventyx Biosciences Trading Down 6.0 %

Shares of VTYX traded down $0.06 during mid-day trading on Friday, reaching $0.94. The company had a trading volume of 1,136,426 shares, compared to its average volume of 1,262,337. Ventyx Biosciences has a fifty-two week low of $0.90 and a fifty-two week high of $5.66. The firm has a fifty day simple moving average of $1.53 and a 200-day simple moving average of $2.00. The stock has a market cap of $66.85 million, a price-to-earnings ratio of -0.40 and a beta of 0.75.

Remove Ads

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.13. As a group, equities analysts predict that Ventyx Biosciences will post -2.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "neutral" rating on shares of Ventyx Biosciences in a research report on Tuesday, January 14th.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.